Autonomix Medical Inc. (AMIX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$2.04 -5.12% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.02

Autonomix Medical Inc. (AMIX) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $4.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AMIX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AMIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Autonomix Medical Inc. (NASDAQ: AMIX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $2.04 (-5.12% 1D, market cap $4.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, AMIX ranks #733 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AMIX compare to XAIR and CODX in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), AMIX carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, XAIR (Beyond Air Inc.) holds a E grade (30/100 RQD, P/E 112.1x, ROIC -35.0%, cap $3.8M) and CODX (Co-Diagnostics Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M). Among the 5-stock peer group, XAIR leads on earnings multiple (112.1x) while AMIX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AMIX?
▼

Per AMIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001617867), Autonomix Medical Inc. generated $0 in revenue, -$16.7M in net income, and -$12.3M in free cash flow against $10.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.02 (-1.11%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (7)Whales (3)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.8% Base Target
$34 Bull$2 Base$1 Bear
📬 FREE AMIX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AMIX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY AMIX SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (26% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 28.4 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
42
Grade D$3.10-14.5% Next Q
Q2 (-2Q)
39
Grade E$2.65-20.8% Next Q
Q3 (-1Q)
37
Grade E$2.10-2.9% Next Q
Current
34
Grade E$2.04-8.7% Hist 90D α
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AMIX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AMIX currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.76) and Max Pain ($2.14) forces dealer call-delta covering toward $34.18.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AMIX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AMIX Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

AMIX Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (AMIX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on AMIX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AMIX)

  • ✓Walkthrough of AMIX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
AMIX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -73.95%🛡️ HOLDING TREND SUPPORT
2026-11-02O $2.15H $2.15L $2.04C $2.04VOL 54.6K
RES: $10.82SUP: $-0.11SMA50: $3.76SMA200: $6.75
$26.28$19.65$13.02$6.38$-0.25RES $10.82SUP $-0.11$2.042026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AMIX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AMIX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AMIX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AMIX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMIX)

Health Care Rank #733 of 1016 ⚔️ XAIR vs AMIX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AMIX vs. XAIR, CODX, ICCM, NVNO)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Autonomix Medical Inc. (AMIX) ranks #733 by composite RQD confidence (34/100, grade E) and #961 by equity capitalization ($4.0M). Within this direct 5-issuer industry benchmark cohort, XAIR leads on earnings valuation at 112.1x trailing P/E, while AMIX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. AMIX currently leads its immediate peer cohort in composite quantitative strength at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AMIX ACTIVE
Autonomix Medical Inc.
E 34/100 — — -35.0% -5.12% $4.0M Benchmark Subject
XAIR
Beyond Air Inc.
E 30/100 112.1x 3.3% -35.0% -2.12% $3.8M /xair-vs-amix →
CODX
Co-Diagnostics Inc.
E 29/100 — 64.3% -35.0% -10.49% $3.5M /codx-vs-amix →
ICCM
IceCure Medical Ltd.
E 34/100 — 36.3% -35.0% -2.13% $3.3M /iccm-vs-amix →
NVNO
enVVeno Medical Corporation
E 33/100 — — -35.0% +4.08% $4.9M /nvno-vs-amix →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001617867

In its most recent audited fiscal period (FY2025, filed 2026-03-31), Autonomix Medical Inc. (AMIX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$16.7M, operating cash flow of -$12.3M, and free cash flow of -$12.3M (-48.6% YoY). On the balance sheet, AMIX closed FY2025 with $10.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-03-31 $0 -$16.7M -$12.3M -$12.3M $10.2M —
FY2024 (FY) 2025-03-31 $0 -$11.4M -$8.3M -$8.3M $12.0M —
FY2023 (FY) 2024-03-31 $0 -$15.4M -$6.6M -$6.6M — —

3. AMIX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AMIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Autonomix Medical Inc. (NASDAQ: AMIX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $2.04 (-5.12% 1D, market cap $4.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, AMIX ranks #733 in composite RQD confidence.

How does AMIX compare to XAIR and CODX in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), AMIX carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, XAIR (Beyond Air Inc.) holds a E grade (30/100 RQD, P/E 112.1x, ROIC -35.0%, cap $3.8M) and CODX (Co-Diagnostics Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M). Among the 5-stock peer group, XAIR leads on earnings multiple (112.1x) while AMIX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AMIX?

Per AMIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001617867), Autonomix Medical Inc. generated $0 in revenue, -$16.7M in net income, and -$12.3M in free cash flow against $10.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AMIX trading relative to its 50-day, 200-day, and 52-week technical levels?

AMIX last traded at $2.04 (-5.12% on volume of 54,588 shares), positioning the stock -45.74% below its 50-day simple moving average ($3.76) and -69.78% below its 200-day simple moving average ($6.75). Across its 52-week range of $1.81 to $32.55, AMIX sits at the 0.7% percentile with a 14-day RSI of 28.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.78 to $2.30).

AMIX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are AMIX insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies AMIX leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $213.66 -0.80% AAPL $348.91 +1.48% MSFT $530.14 -0.16% TSLA $403.30 -0.23% PLTR $196.42 -0.20% SOFI $17.61 +2.74% IBIT $43.36 -0.94% GLD $355.78 -1.34%